Stay updated on Combination Nivolumab & PD-L1/IDO Vaccine in Melanoma Clinical Trial

Sign up to get notified when there's something new on the Combination Nivolumab & PD-L1/IDO Vaccine in Melanoma Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Combination Nivolumab & PD-L1/IDO Vaccine in Melanoma Clinical Trial page

  1. Check
    yesterday
    No Change Detected
  2. Check
    8 days ago
    Change Detected
    Summary
    The record describes a completed Phase 1/2 study of nivolumab combined with a PD-L1/IDO peptide vaccine for metastatic melanoma, including its participant criteria, treatment schedule, and measured outcomes. It also provides study publications, investigator details, and a study protocol document.
    Difference
    52%
    Check dated 2026-11-08T13:07:58.000Z thumbnail image
  3. Check
    15 days ago
    Change Detected
    Summary
    The footer revision label changed from v3.7.2 to v3.8.0; the study page still displays a 403 Forbidden error.
    Difference
    0.2%
    Check dated 2026-11-01T13:53:03.000Z thumbnail image
  4. Check
    22 days ago
    Change Detected
    Summary
    A banner was added announcing an NIH website transition and linking to updates and FAQs. It appears above the 403 error page.
    Difference
    1%
    Check dated 2026-10-25T13:19:17.000Z thumbnail image
  5. Check
    29 days ago
    Change Detected
    Summary
    The displayed site revision changes from v3.7.1 to v3.7.2.
    Difference
    0.2%
    Check dated 2026-10-18T13:27:38.000Z thumbnail image
  6. Check
    36 days ago
    Change Detected
    Summary
    The footer revision changed from v3.7.0 to v3.7.1 while the page continued to display a 403 Forbidden error.
    Difference
    0.2%
    Check dated 2026-10-11T14:43:06.000Z thumbnail image
  7. Check
    56 days ago
    Change Detected
    Summary
    The page now displays a 403 Forbidden error, replacing the study record content and navigation for this URL. Access to the study details is blocked.
    Difference
    19%
    Check dated 2026-09-20T22:36:29.000Z thumbnail image

Stay in the know with updates to Combination Nivolumab & PD-L1/IDO Vaccine in Melanoma Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Combination Nivolumab & PD-L1/IDO Vaccine in Melanoma Clinical Trial page.